New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management Alnylam (Nasdaq: ALNY) presented ACC.26 data showing vutrisiran improves quality of life and clinical outcomes in ATTR-CM and real-world adherence is high. Vutrisiran reduced progression to advanced disease (8.0% vs 10.7% placebo) and lowered risk of death/CV events by up to 77% in subgroups. A pooled Phase 2 analysis found zilebesiran’s safety profile acceptable, supporting the ongoing ZENITH Phase 3 CVOT initiated September 2025.

#ALNY New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

www.stocktitan.net/news/ALNY/new-data-prese...

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association Alnylam (Nasdaq: ALNY) announced partnerships to advance earlier diagnosis and coordinated care for transthyretin-mediated cardiomyopathy (ATTR-CM).The company will partner with Viz.ai to deploy an FDA-cleared echocardiography AI (Us2.ai) and launch the multi-system AWARE study at five pilot health systems later this year. Alnylam also supports a three-year American Heart Association learning collaborative with a 10-site cohort. A webinar is scheduled today at 9:30 am ET, with an archived webcast available ~two hours after the event.

#ALNY Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

www.stocktitan.net/news/ALNY/alnylam-advanc...

#ALNY #7d4caac2-0bf1-46af-a504-9413de34606f #investing #Health #Care

Origin | Interest | Match

$ALNY Earnings Alert: Can TTR Drug Save the Day?
Alnylam Pharmaceuticals reports Q4 2025 results Thursday, investors await TTR drug update
#ALNY #BiotechStocks #EarningsSeason

https://a777.lt/re2pTG

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced its new five-year strategy,“ Alnylam 2030,” focused on scaling the Company’ s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and...

#ALNY Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

www.stocktitan.net/news/ALNY/alnylam-launch...

#ALNY Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

www.stocktitan.net/news/ALNY/alnylam-to-inv...

Lululemon to exit Nasdaq 100 with Seagate among additions Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others considered for additions. Read more here.

Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions

#lulu #ttd #alny #qqq #stx #wdc #biib #mpwr #on #insm #cdw

Origin | Interest | Match

Alnylam (Nasdaq: ALNY) sets private cash buyback of $34.4M 1.00% notes, $362.8M left Alnylam plans privately negotiated cash repurchases of $34.4M principal of its 1.00% 2027 convertible notes, with about $362.8M in notes expected to remain outstanding.

#ALNY Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

www.stocktitan.net/news/ALNY/alnylam-announ...

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM Alnylam (Nasdaq: ALNY) presented post hoc HELIOS-B analyses at AHA 2025 showing vutrisiran improved cardiac structure and function and preserved renal function in ATTR-CM patients.Key imaging findings: CMR showed amyloid regression in 22% of treated patients vs 0% placebo at Year 3; mean ECV change was -0.10% with vutrisiran vs +7.86% with placebo (p=0.006). Renal results: fewer patients had ≥40% eGFR decline (12.7% vs 21.2%) and treatment reduced risk of death and CV events in patients progressing to CKD stage 4+ (HR 0.47; 95% CI 0.26–0.85).

#ALNY New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

www.stocktitan.net/news/ALNY/new-post-hoc-a...

11,000 Patients, 35 Countries: Alnylam's Massive Phase 3 Trial Targets Uncontrolled Hypertension Crisis RNAi biotech Alnylam initiates ZENITH Phase 3 trial of biannual zilebesiran in 11,000 patients across 35 countries. Study targets cardiovascular risk in uncontrolled hypertension, triggers $300M Roche milestone.

#ALNY Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

www.stocktitan.net/news/ALNY/alnylam-announ...

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) at the HFSA Annual Scientific Meeting 2025. The data showed that vutrisiran treatment led to 37-49% lower rates of gastrointestinal events in ATTR-CM patients compared to placebo.Key findings include a 42% reduction in GI events in the overall population, with consistent benefits observed across monotherapy and baseline tafamidis groups. For specific symptoms like diarrhea, nausea, and vomiting, reductions of over 50% were observed. A separate analysis demonstrated a statistically significant 32% reduction in the risk of all-cause mortality and recurrent cardiovascular events through 36 months in the monotherapy group.The study results supported recent approvals of AMVUTTRA for ATTR-CM treatment in multiple regions including the US, EU, and Japan, with over 8,000 patient-years of worldwide experience.

#ALNY New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

www.stocktitan.net/news/ALNY/new-data-from-...

$575M Zero-Interest Notes: Alnylam's Strategic Move Includes $638M Debt Repurchase Plan Alnylam prices $575M convertible notes due 2028 at 0% interest with 40% conversion premium. Plans to repurchase $638M of existing 2027 notes. Includes capped call transactions to reduce dilution.

#ALNY Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

www.stocktitan.net/news/ALNY/alnylam-announ...

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new long-term data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) at ESC Congress 2025. The results demonstrate sustained benefits through 48 months in treating ATTR-CM (transthyretin-mediated amyloidosis with cardiomyopathy).Key findings show vutrisiran reduced the risk of all-cause mortality or first cardiovascular event by 37% in the overall population and 42% in the monotherapy group. The drug maintained improvements in quality of life measures and cardiac biomarkers during the 12-month open-label extension period. The study included 654 patients, with 466 entering the extension phase.The safety profile remained consistent with previous findings, with no new concerns identified. The data supported recent approvals in multiple regions including the US, EU, Japan, and UK, making AMVUTTRA the first RNAi therapeutic approved for both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

#ALNY New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

www.stocktitan.net/news/ALNY/new-data-from-...

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results...

#ALNY Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

www.stocktitan.net/news/ALNY/alnylam-to-adv...

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension Genentech, a member of the Roche Group and Alnylam today announced the decision to initiate a Phase III cardiovascular outcomes trial to evaluate the ability of zilebesiran, an RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA...

#RHHBY #ALNY Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

www.stocktitan.net/news/RHHBY/genentech-and...

2/ 📈 GANADORAS

Energizer: superó ganancias y elevó su pronóstico anual de ingresos y beneficios #ENR

Tyson Foods: bate expectativas de ingresos y beneficios para su segundo trimestre #TSN

Alnylam: ventas récord de su fármaco y mejora de recomendación de analistas #ALNY

Alnylam Earnings: TTR Drug Sales Soar 77% as AMVUTTRA Dominates, Company Boosts Revenue Forecast Q2 revenues hit $672M driven by AMVUTTRA's success in ATTR-CM. Multiple global approvals fuel growth as Alnylam raises full-year guidance. See full results.

#ALNY Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

www.stocktitan.net/news/ALNY/alnylam-pharma...

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Alnylam Pharmaceuticals (ALNY) has received European Commission approval for AMVUTTRA (vutrisiran) to treat ATTR amyloidosis with cardiomyopathy, making it the first RNAi therapeutic approved for this condition in Europe. The approval is based on the HELIOS-B Phase 3 study results, which demonstrated a 28% reduction in composite all-cause mortality and cardiovascular events, and up to 36% reduction in all-cause mortality through 42 months. The drug, administered quarterly, showed significant improvements in functional capacity and quality of life. AMVUTTRA works by reducing disease-causing TTR protein, addressing approximately 100,000 affected patients across Europe. The approval follows recent authorizations in the U.S. and Brazil, with similar safety profiles to placebo in clinical trials.

#ALNY Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

www.stocktitan.net/news/ALNY/alnylam-receiv...

www.fool.com/investing/2025/05/24/3-h...

#ALNY #AXSM #SMMT #68c6e7b8-2960-4f6a-84d9-f08d8538d507 #investing

Result Details

Alnylam ESG Report: 100% Renewable Energy Sites, 88% Employee Satisfaction Score Revealed New sustainability report showcases verified emissions data, renewable energy adoption, and global health equity progress. See complete ESG metrics and initiatives.

#ALNY Alnylam Issues 2024 Corporate Responsibility Report

www.stocktitan.net/news/ALNY/alnylam-issues...

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress Alnylam Pharmaceuticals (NASDAQ: ALNY) will present new data from its TTR amyloidosis franchise at the Heart Failure 2025 Congress in Belgrade. Key highlights include additional analyses of the HELIOS-B Phase 3 study of vutrisiran in ATTR-CM patients, featuring extended 42-month data on cardiovascular outcomes. The presentation follows recent AMVUTTRA® (vutrisiran) approvals in the U.S. and Brazil for treating cardiomyopathy in adults with wild-type or hereditary transthyretin-mediated amyloidosis, along with a positive CHMP opinion in Europe. The congress will also showcase the TRITON-CM Phase 3 study design for nucresiran (ALN-TTRsc04) and analysis of vutrisiran's effectiveness in patients who progressed on tafamidis treatment.

#ALNY Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

www.stocktitan.net/news/ALNY/alnylam-to-sha...

$IPHA BULLRUN Chart + Positive News with #Sanofi Deal. 300% = $8.00 PT

#SNY #SANOFI
#VRTX #REGN
#ARGX #ALNY

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B Alnylam Pharmaceuticals (Nasdaq: ALNY) announces FDA approval of Qfitlia™ (fitusiran), marking a significant breakthrough as the first siRNA therapeutic for hemophilia A or B treatment. This represents Alnylam's sixth approved RNAi therapeutic in the US.Qfitlia works by lowering antithrombin (AT), a protein that inhibits blood clotting, and is approved for routine prophylaxis in patients 12 years and older with hemophilia A or B, with or without inhibitors. Clinical studies demonstrated a 90% reduction in annualized bleeding rates through subcutaneous injections administered every two months.Under a collaboration agreement with Sanofi, who holds global development and commercialization rights, Alnylam is eligible to receive tiered royalties of 15-30% on global net sales. The treatment has potential to benefit an estimated one million people worldwide living with hemophilia A and B. Regulatory submissions have also been completed in China and Brazil.

#ALNY FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

www.stocktitan.net/news/ALNY/fda-approves-q...

Top 10/Bottom 10 Non-S&P 500 Companies by Market Cap Change for the week ending 3/21/2025, #app and #alny biggest gains, #srpt and #rkt biggest losses.

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day Alnylam Pharmaceuticals highlighted significant progress in its R&D pipeline at its R&D Day event. Key updates include:Phase 3 TRITON program for nucresiran in ATTR-CM and hATTR-PN, aiming for over 95% knockdown with twice-annual dosing.Phase 3 trial for zilebesiran to transform hypertension treatment, enrolling up to 11,000 patients globally.New programs for Huntington’s disease, bleeding disorders, and type 2 diabetes.Platform advances for improved delivery solutions and manufacturing innovations.Data from the HELIOS-B study showed vutrisiran reduced all-cause mortality by 36% in patients with ATTR amyloidosis with cardiomyopathy. Vutrisiran is under FDA review with a target action date of March 23, 2025.Alnylam is committed to expanding its RNAi therapeutics, targeting all major tissue types by 2030. The company will file IND applications for nine new programs by 2025, including two in new tissues, two in the CNS, and five in the liver.The event was webcast live and a replay will be available on Alnylam's website.

#ALNY Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

www.stocktitan.net/news/ALNY/alnylam-highli...